Focused Ultrasound (FUS) is an innovative, non-invasive therapeutic technology with the potential to revolutionize treatment, improve patient outcomes, and reduce costs by serving as an alternative or complement to surgery, radiation therapy, drug delivery, and immunotherapy.

This novel technology delivers concentrated beams of ultrasonic energy to precise targets deep in the body, which stimulate a variety of therapeutic effects on the targeted area without damaging surrounding healthy tissue. The diversity of effects, which can be achieved without incisions or the use of ionizing radiation, enables the treatment of more than 60 conditions, including tumors of the brain, breast, prostate, liver and pancreas; Parkinson’s and Alzheimer’s disease; epilepsy; depression; obsessive compulsive disorder; arthritis; and neuropathic pain.

Improved imaging techniques and advances in technology have enabled focused ultrasound to provide non-invasive, targeted, personalized treatment for a wide range of diseases, resulting in cures, reduced pain, and fewer complications.

It can take decades for a new therapeutic technology to become mainstream. Every year that we can shave off of that process can reduce patient death, disability, and suffering.

The Focused Ultrasound Foundation is a unique research, education, and advocacy organization established to save lives by accelerating the development and adoption of focused ultrasound technology. Since its inception in 2006, the Foundation has developed a high-impact, results-oriented approach to achieve its goals and shorten the time from technology development to widespread patient treatment by:

- **Influencing the direction of the field**: identifying priorities and defining areas of clinical benefit
- **Creating knowledge**: funding research to evaluate the feasibility, safety, efficacy, and cost-effectiveness of focused ultrasound therapy for use by a wide range of stakeholders
- **Fostering collaboration**: encouraging the exchange of information among stakeholders to stimulate innovation and increase the pace of technology development
- **Increasing awareness**: aggregating and disseminating knowledge through our website and social media, newsletter, and online journal

This work is made possible by the philanthropic support of our donors, who recognize the urgent needs of patients, the potential of focused ultrasound, and the value of the Foundation’s disciplined, entrepreneurial approach.
This chart portrays the global status of focused ultrasound as it evolves to widespread adoption. The number of indications is increasing rapidly, but most are in the early stages of development.

<table>
<thead>
<tr>
<th>ADOPTION STATUS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FOCUSED ULTRASOUND AT-A-GLANCE</strong></td>
</tr>
</tbody>
</table>

**Oncological**
- Bone Metastases
- Prostate Cancer
- Breast Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Soft Tissue Tumors
- Brain Tumors
- Pediatric Neuroblastoma
- Head & Neck Cancer
- Lung Cancer
- Ovarian Cancer
- Bladder Cancer
- Colon Cancer
- Esophageal Cancer

**Musculoskeletal**
- Back Pain
- Osteoid Osteoma
- Osteoarthritis
- Disc Degeneration
- Muscle Atrophy
- Sarcoidosis
- Spinal Cord Injury
- Spinal Tumors

**Neurological**
- Essential Tremor
- Neuropathic Pain
- Parkinson’s Disease
- Brain Tumors
- Depression
- OCD
- Alzheimer’s Disease
- Epilepsy
- Hydrocephalus
- Multiple Sclerosis
- Stroke
- Traumatic Brain Injury
- Trigeminal Neuralgia
- AVM’s
- Cancer Pain

**Cardiovascular**
- Hypertension
- Atherosclerosis
- Atrial Fibrillation
- Deep Vein Thrombosis
- Heart Block
- HLHS
- Periperal Artery Disease
- Septal Perforation

**Urological**
- Prostate Cancer
- Kidney Cancer
- Benign Prostatic Hyperplasia
- Acute Kidney Injury
- Acute Tubular Necrosis
- Ureteroscopy
- Bladder Cancer

**Women’s Health**
- Uterine Fibroids
- Breast Fibroadenomas
- Uterine Adenomyosis
- Tubal Pregnancy
- Fetal Surgery
- Ovarian Cancer
- Polycystic Ovarian Syndrome

**Musculoskeletal**

**Endocrine Disorders**
- Thyroid Nodules
- Diabetes
- Obesity

**Miscellaneous**
- Hypersplenism

---

**BOARD OF DIRECTORS**

- **Neal F. Kassell, MD**  
  Chairman, Founder; Focused Ultrasound Foundation  
  Professor of Neurosurgery, University of Virginia

- **Dorothy N. Batten**  
  Director, Amazon Conservation Association  
  Former Director, Landmark Communications, Inc.

- **Lodewijk J.R. de Vink**  
  Founding Partner, Blackstone Healthcare Partners, LLC  
  Former Chairman & CEO, Warner-Lambert

- **Eugene V. Fife**  
  Founding Principal, Vawter Capital, LLC  
  Former Chairman, Goldman Sachs International

- **John R. Grisham**  
  Author

- **Daniel P. Jordan, PhD**  
  President Emeritus, Thomas Jefferson Foundation, Inc.

- **Edward J. “Ned” Kelly, III, JD**  
  Former chairman, Citigroup, Inc

- **Edward D. Miller, MD**  
  Former CEO, Johns Hopkins Medicine

- **Frederic H. Moll, MD**  
  Co-founder, Intuitive Surgical  
  Chairman & CEO, Auris Surgical Robotics, Inc.

- **Steve H. Rusckowski**  
  President and CEO, Quest Diagnostics, Inc.  
  Former CEO, Philips Healthcare

- **Charles Steger, PhD**  
  Executive Director, Global Forum on Urban and Regional Resilience  
  Former President, Virginia Tech

- **Andrew C. von Eschenbach, MD**  
  President, Samaritan Health Initiative  
  Former Commissioner, U.S. Food and Drug Administration  
  Former Director, National Cancer Institute

- **Carl P. Zeithaml, PhD, MBA**  
  Dean, University of Virginia’s McIntire School of Commerce

---

For more information, visit www.fusfoundation.org or contact:
- Susan Klees | Director of Communications  
  sklees@fusfoundation.org
- 1230 Cedars Court, Suite 206, Charlottesville, VA 22903, 434.220.4993